Chief Commercial Officer
Mr. Philippe Drouet has served as our Chief Commercial Officer since February 2021. He brings more than 20 years of experience in global pharmaceutical marketing, along with demonstrated leadership in the launch and commercialization of important medicines across different therapeutic areas in the United States and other key markets. Prior to joining our company, Phillipe served as Senior Vice President, Global Oncology Marketing & Market Access at Merck & Co., where he launched and commercialized Keytruda®, drove substantial global oncology revenue and built and led the company’s Global Marketing, Access and Pricing Organization. Previously, he served as President of Hospira’s U.S. division before Hospira’s acquisition by Pfizer in 2015. Prior, Philippe held roles of increasing responsibility at Novartis Pharmaceutical Corporation, including Vice President, U.S. Hematology; at Novartis, he led in-country marketing efforts in the United States, Canada, the United Kingdom and Turkey and was responsible for the launch and commercialization of Gleevec® and Exjade®. He received an M.B.A. from INSEAD and Master of Science and Bachelor of Engineering from McGill University.
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.